Investment
Features
FeesSafety
Academy
More
Pluang+

Whitbread's Premier Inn faces rising UK competition and cannibalisation, says UBS ahead of full-year results.

Market News
13 Apr 2026
Proactive Investors
View Source
Neutral
pluang ai news

UBS reports that Whitbread's Premier Inn brand remains strong in the UK hotel market but faces increasing competition, with the average number of nearby rivals rising from 3.97 in 2019 to 4.6 now. Cannibalisation, where new sites overlap with existing ones, has also increased slightly to about 76%, indicating more internal competition as the chain expands. Despite these challenges, Whitbread maintains a strong market position. Investors are awaiting the company's full-year results on 30 April, which could influence the stock's next move.

More News

Sodexo wins major global catering contract with Meta for 130+ sites in 30+ countries

Sodexo wins major global catering contract with Meta for 130+ sites in 30+ countries

Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...

Market News
Bullish
2 hours ago
Thor Explorations stays on track with gold production and strong cash position in Q2 2026.

Thor Explorations stays on track with gold production and strong cash position in Q2 2026.

Thor Explorations produced 19,153 ounces of gold in Q2 2026 from its Segilola mine in Nigeria, maintaining its full-year production guidance of 75,000 to 85,000 ounces. The company generated $77.3 million in revenue by selling 17,050 ounces at an ave...

Company Fundamentals
Bullish
4 hours ago
Angelini Pharma completes $4.1B acquisition of Catalyst, expanding US presence and brain health leadership.

Angelini Pharma completes $4.1B acquisition of Catalyst, expanding US presence and brain health leadership.

Angelini Pharma has finalized its $4.1 billion acquisition of Catalyst Pharmaceuticals, enhancing its footprint in the U.S. market and strengthening its global leadership in brain health and rare diseases. The deal includes significant investments fr...

Company Fundamentals
Bullish
4 hours ago
Greenwich LifeSciences' breast cancer drug shows strong Phase 2 results but faces funding risks ahead of Phase 3.

Greenwich LifeSciences' breast cancer drug shows strong Phase 2 results but faces funding risks ahead of Phase 3.

Greenwich LifeSciences is developing GLSI-100, an immunotherapy targeting HER2-positive breast cancer, currently in Phase 3 trials. The drug showed a 70-80% reduction in cancer recurrence in Phase 2b, outperforming existing treatments with no serious...

Analyst Insights
Bullish
4 hours ago
Ethereum breaks $1,900 resistance, fueled by strong buying and short liquidations

Ethereum breaks $1,900 resistance, fueled by strong buying and short liquidations

Ethereum (ETH) surged past the $1,894.89 resistance level, accelerating its recovery toward the $1,940–$1,950 zone after days of consolidation. This breakout was supported by lower-than-expected U.S. inflation data, which boosted risk appetite and bu...

Technical Signals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App